About Cesca Therapeutics
Cesca Therapeutics is a company based in Rancho Cordova (United States) founded in 1986. Cesca Therapeutics has completed 1 acquisition, including SynGen. Cesca Therapeutics operates in a competitive market with competitors including Insitro, BridgeBio, ATAI, Forge Biologics and Spark Therapeutics, among others.
- Headquarter Rancho Cordova, United States
- Stage Public
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website cescatherapeutics.com
- Social LinkedIn X Facebook
- Legal Name Totipotentsc Scientific Product Private Limited
- Date of Incorporation 28 Mar, 2008
- Jurisdiction Gurugram, Haryana, India
- Annual Revenue₹2.15 Cr
FY 2017 · -21% YoY
- Net Loss-₹51.2 Lakh
FY 2017 · -24% margin
- EBITDA-₹42 Lakh
FY 2017 · -20% margin
- Latest Funding Round$800K (USD), Post-IPO
Feb 2019
- Investors
- Investments & Acquisitions
Associated legal entities of Cesca Therapeutics
Cesca Therapeutics operates through Totipotentsc Scientific Product Private Limited (amalgamated). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2017) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Totipotentsc Scientific Product Private Limited CIN U73100HR2008PTC041429 | Amalgamated | 28 Mar 2008 | Gurugram, Haryana | ₹2.2 Cr | – | 5 | View details |
Funding Insights of Cesca Therapeutics
- Total Rounds 7
- Last Round Post-IPO — $800,000
- First Round $7.01M
(Jun 2002)
- Investors Count 1
All 7 funding rounds of Cesca Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2019 | $800,000 | Post-IPO | – | – | – |
| Nov 2017 | $2.6M | Post-IPO | – | – | – |
| Feb 2016 | $15M | Post-IPO | – | – | |
| Sep 2015 | $15M | Post-IPO | – | – | – |
| Jan 2014 | $6.67M | Post-IPO | – | – | – |
| Apr 2003 | $5.63M | Post-IPO | – | – | – |
| Jun 2002 | $7.01M | Post-IPO | – | – | – |
1 investors in total: 1 institutional.
Investors in Cesca Therapeutics
Cesca Therapeutics has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Boyalife Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
- | 2009 | boyalifegroup.com | Wuxi, China |
Investor details for Cesca Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Totipotentsc Scientific Product Private Limited (Cesca Therapeutics)
Totipotentsc Scientific Product Private Limited is the primary company behind Cesca Therapeutics. The board of Totipotentsc Scientific Product Private Limited currently have 5 directors; the longest-serving is Xiaochun Xu, appointed in 2017. 9 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Xiaochun Xu DIN 07824128 | Director | 02 Jun 2017 | 9 yrs 4 mo | Totipotentsc Scientific Product Private Limited |
| Dalip Sethi DIN 07919303 | Additional Director | 29 Aug 2017 | 9 yrs 1 mo | Totipotentsc Scientific Product Private Limited |
| Ankita Jaiswal DIN 08007161 | Additional Director | 01 Dec 2017 | 8 yrs 10 mo | Totipotentsc Scientific Product Private Limited |
| Monika Sharma DIN 08147484 | Additional Director | 01 Jun 2018 | 8 yrs 4 mo | Totipotentsc Scientific Product Private Limited |
| Nitin Chaturvedi DIN 03258709 | Alternate Director | 20 Jun 2018 | 8 yrs 3 mo | Totipotentsc Scientific Product Private Limited |
People of Cesca Therapeutics
6 people are tracked at Cesca Therapeutics (1 in leadership, 3 in board & advisors, 2 in team).
| Name | Role | Group |
|---|---|---|
Darrell Drysen | Vice President Of Operations, Sr. Project Manager | Leadership |
Joseph Jeff Thomis | Director | Board & advisors |
James Xu | Director | Board & advisors |
Biao Xi | Director | Board & advisors |
Jesus Ernesto Echevarria Barron | Sr. Project Engineer | Team |
Ryan Scally | Facilities Manager and Project Coordinator | Team |
Complete people profiles for Cesca Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of Cesca Therapeutics
Figures of Totipotentsc Scientific Product Private Limited, the primary company behind Cesca Therapeutics, for FY 2017. Revenue was ₹2.15 Cr (-21% year on year). Net loss was -₹51.2 Lakh (-24% margin). EBITDA was -₹42 Lakh (-20% margin).
- ₹2.15 CrRevenue · FY 2017 · -21% YoY
- -₹51.2 LakhNet loss · -24% margin
- -₹42 LakhEBITDA · -20% margin
- ₹1.70 CrPaid-up capital
Balance sheet, profit and loss, cash flow and ratios of Totipotentsc Scientific Product Private Limited are on its company page.
Detailed financial statements for Cesca Therapeutics
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Cesca Therapeutics
Cesca Therapeutics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include SynGen.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Develops cell separation tools and accessories | syngeninc.com | Sacramento, United States | 2009 | Jul 2017 | •••• |
Complete acquisition details for Cesca Therapeutics
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Cesca Therapeutics
5 dated milestones of Cesca Therapeutics across 33 years, from founding to its latest funding, stage changes and deals.
- Founded Cesca Therapeutics is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $7.0M.
- Acquisition Acquires SynGen.
- Funding Latest funding round, Post-IPO, of $800K.
Competitors of Cesca Therapeutics
Cesca Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Insitro, BridgeBio, ATAI, Forge Biologics and Spark Therapeutics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| insitro.com | 2018 | San Francisco, United States | $643.21M | 257 | An AI-enabled platform is developed for infectious disease treatment. | |
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | – | Therapeutics for genetic diseases are developed through targeted interventions. | |
| atai.life | 2018 | Munich, Germany | $386.67M | – | A biopharmaceutical company accelerating innovative mental health treatments. | |
| forgebiologics.com | 2020 | Columbus, United States | $250M | 118 | Gene therapies for rare diseases are developed to treat patients. | |
| sparktx.com | 2013 | Philadelphia, United States | $82.8M | 822 | Gene therapies for rare diseases including retinal dystrophies are developed. | |
| cariboubio.com | 2011 | Berkeley, United States | $156.55M | 92 | Provider of cell therapies to treat cancer and hematologic conditions | |
| kriyatherapeutics.com | 2012 | Redwood, United States | $930.93M | 159 | Developer of therapeutic solutions for the treatment of diabetes | |
| strandtx.com | 2017 | Cambridge, United States | $103.14M | 47 | mRNA therapeutics platform is provided for multi-functional treatments. | |
| editasmedicine.com | 2013 | Cambridge, United States | $210M | 257 | Therapeutics for rare genetic diseases are developed using CRISPR technology. |
Detailed competitors of Cesca Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Cesca Therapeutics
Websites that share an audience with Cesca Therapeutics (cescatherapeutics.com).
Websites whose visitors overlap most with Cesca Therapeutics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| athersys.com | 100% | 1.7K | #8,716,189 | View details |
Latest news on Cesca Therapeutics
Complete news archive for Cesca Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Cesca Therapeutics
10 companies that operate in the same segment as Cesca Therapeutics (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 265 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Cesca Therapeutics
Cesca Therapeutics was founded in 1986 and raised its 1st funding round 16 years after it was founded.
Cesca Therapeutics is headquartered in Rancho Cordova, United States. It is registered at Rancho Cordova, California, United States.
The primary company behind Cesca Therapeutics, Totipotentsc Scientific Product Private Limited, reported revenue of ₹2.15 Cr for FY 2017, down 21% year on year.
Cesca Therapeutics is engaged in the development of cell-based therapeutics as regenerative medicine. It was formed by the merger of Thermogenesis which supplies a supplier of enabling technologies for the processing and storage of stem cells and TotipotentRx which develops cell-based therapies. Its lead therapeutic technology platform SurgWerks harvests, selects and delivers a dose of autologous bone marrow derived or peripheral blood-derived cells and proteins. The technology is currently in clinical trials as a potential treatment for acute myocardial infarction, critical limb ischemia, and orthopedic injuries. It also manufactures devices created specifically for regenerative medicine. Besides, it also provides cell manufacturing and banking services.
Cesca Therapeutics's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
Cesca Therapeutics has made 1 acquisition, including SynGen.
Cesca Therapeutics has 1 investor. Key investors include Boyalife Group.
Cesca Therapeutics operates through Totipotentsc Scientific Product Private Limited.
The legal entities of Cesca Therapeutics currently have 5 directors, including Xiaochun Xu, Dalip Sethi, Monika Sharma and others.